With RC220 the main thing to prove was that there were no crystallisation or associated inflammation (phlebitis). The efficacy should be unchanged from RC110 given it’s the same compound. This should now fit nicely into the clinical plans as part of the strategy update.
Race is getting back to kicking goals which we all like. AML news around the corner. Getting exciting.
No advice.
Ann: RC220 Peripheral Infusion Safety Confirmed, page-8
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
